Literature DB >> 10199270

Chondrosarcoma of bone: an assessment of outcome.

F Y Lee1, H J Mankin, G Fondren, M C Gebhardt, D S Springfield, A E Rosenberg, L C Jennings.   

Abstract

BACKGROUND: The data on 227 patients who had been managed for a chondrosarcoma at one institution were reviewed to determine the nature of the lesions, the predictors of outcome, and whether there were any ways to change the treatment approaches to improve the results.
METHODS: The patients were followed for a mean duration of six years (range, three to twenty-five years). The mean age of the patients was forty-seven years (range, nine to eighty-four years). The most prevalent sites of the tumors were the femur (seventy-eight), the pelvis (fifty-one), and the humerus (thirty-nine). The tumors were divided into two groups according to histological grade. Eighty-six tumors (sixteen atypical enchondromas and seventy grade-1 chondrosarcomas) that were locally destructive but were associated with a low likelihood of metastasis were considered to be low-grade. The remaining 141 lesions, which were locally destructive, potentially metastatic, and capable of causing death, were thought to be high-grade. One hundred and three of these 141 lesions were grade 2, and thirty-eight were grade 3 (eighteen of the thirty-eight were grade 3 only, and twenty were both grade 3 and dedifferentiated). Two hundred and twenty-four patients were managed with resection and a limb-sparing procedure; the remaining three patients had an amputation. Postoperative adjuvant radiation was used for fifty-six patients; chemotherapy, for thirty-five; and both radiation and chemotherapy, for nineteen. Flow cytometric patterns were analyzed for 105 patients.
RESULTS: The patients who had a high-grade tumor were older than those who had a low-grade tumor (mean age [and standard deviation], 50+/-17.0 years compared with 40+/-15.9 years; p < 0.001). Pathological fracture, metastasis, local recurrence, and death were more prevalent in the group that had a high-grade lesion (p < 0.001). Predictors of metastasis and death in that group of patients included local recurrence, a pelvic location of the tumor, a tumor that was more than 100 cubic centimeters in size, a ploidic abnormality (aneuploidy coupled with a high mean DNA index), a histological grade of 3, and a dedifferentiated type of tumor (p < 0.001).
CONCLUSIONS: Although the data are suggestive, with the numbers available for study we could not detect a significant difference in the rates of pulmonary metastasis and death between the patients who had a grade-3 lesion and those who had a grade-3 lesion that was also dedifferentiated. However, the interval between diagnosis and death was 32+/-22.8 months for the patients who had a grade-3 lesion compared with 5+/-3.7 months for those who had a grade-3 lesion that was also dedifferentiated (p < 0.001). Overall, patients who had had a resection with wide margins (margins extending outside the reactive zone) had a longer duration of survival than did those who had had a so-called marginal resection (margins extending outside the tumor but within the reactive zone) or an intralesional resection (margins within the lesion) (p < 0.04). Adjunctive chemotherapy or radiation, or both (which, it must be noted, was used, without a protocol, in a relatively small number of patients), after an intralesional resection, for recurrent disease, or for distant metastasis did not appear to alter the outcome.

Entities:  

Mesh:

Year:  1999        PMID: 10199270     DOI: 10.2106/00004623-199903000-00004

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  110 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  New cell lines with chondrocytic phenotypes from human chondrosarcoma.

Authors:  Ikuo Kudawara; Nobuhito Araki; Akira Myoui; Yoichi Kato; Atsumasa Uchida; Hideki Yoshikawa
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

3.  [Primary malignant bone tumors].

Authors:  R von Eisenhart-Rothe; A Toepfer; M Salzmann; J Schauwecker; H Gollwitzer; H Rechl
Journal:  Orthopade       Date:  2011-12       Impact factor: 1.087

4.  Low-grade chondrosarcoma of bone: experiences from the Vienna Bone and Soft Tissue Tumour Registry.

Authors:  Philipp T Funovics; Joannis Panotopoulos; Manuel Sabeti-Aschraf; Farshid Abdolvahab; Josef M Funovics; Susanna Lang; Rainer I Kotz; Martin Dominkus
Journal:  Int Orthop       Date:  2010-08-28       Impact factor: 3.075

Review 5.  Therapeutic molecular targets in human chondrosarcoma.

Authors:  Nuor Jamil; Sarah Howie; Donald M Salter
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

Review 6.  The clinical management of chondrosarcoma.

Authors:  Richard F Riedel; Nicole Larrier; Leslie Dodd; David Kirsch; Salutario Martinez; Brian E Brigman
Journal:  Curr Treat Options Oncol       Date:  2009-02-24

7.  A reproducible and simple grading system for classical chondrosarcomas. Analysis of 35 chondrosarcomas and 16 enchondromas with emphasis on recurrence rate and radiological and clinical data.

Authors:  Heike Welkerling; Susanne Kratz; Volker Ewerbeck; Günter Delling
Journal:  Virchows Arch       Date:  2003-09-25       Impact factor: 4.064

8.  The impact of pathological fractures on therapy outcome in patients with primary malignant bone tumours.

Authors:  Babak Moradi; Anita Zahlten-Hinguranage; Burkhard Lehner; Felix Zeifang
Journal:  Int Orthop       Date:  2009-12-13       Impact factor: 3.075

9.  Extended intralesional treatment versus resection of low-grade chondrosarcomas.

Authors:  Chad Aarons; Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

10.  Grade I chondrosarcoma of bone: the Münster experience.

Authors:  Arne Streitbürger; Helmut Ahrens; Maurice Balke; Horst Buerger; Winfried Winkelmann; Georg Gosheger; Jendrik Hardes
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.